Prostate Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Prostate Cancer is a ~$2.2B Part D market with mature, androgen-receptor-focused therapeutics entering consolidation as patent cliffs approach.
Key Trends
- Androgen receptor (AR) inhibitors dominate 73% of market share (ERLEADA + NUBEQA); GnRH agonists/antagonists represent legacy backbone therapy
- Patent cliff risk: RAYOS (2028), LUPRON DEPOT (approaching), and peak-lifecycle AR inhibitors face LOE by 2040–2042
- Minimal pipeline innovation: 1,759 trials ongoing but heavily weighted to Phase 2 (537 trials); few emerging mechanisms beyond established AR/GnRH pathways
Career Verdict
A stable, commercially mature area suitable for specialists seeking market depth and legacy-drug stewardship, but limited upside for those pursuing cutting-edge oncology innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ERLEADA (apalutamide) | Johnson & Johnson | $1.1B | 50% | Peak | Stable | 13.6yr |
| 2 | NUBEQA (darolutamide) | Bayer | $576M | 26% | Peak | Stable | 16.0yr |
| 3 | ORGOVYX (relugolix) | Sumitomo Dainippon Pharma | $277M | 13% | Peak | Stable | 11.3yr |
| 4 | LUPRON DEPOT (leuprolide acetate) | AbbVie | $129M | 6% | LOE_Approaching | Declining |
Drug Class Breakdown
market consolidation around ERLEADA + NUBEQA duopoly
legacy backbone; gradual erosion as AR inhibitors preferred
minimal market penetration; largely displaced by newer AR inhibitors
niche; limited clinical relevance in primary market
Career Outlook
StableProstate cancer represents a mature, consolidating market with predictable commercial dynamics and strong incumbency by J&J and Bayer. Job security is high, compensation competitive, and career paths well-defined; however, innovation velocity is low and disruption risk is concentrated in patent cliff windows (2028–2042). Specialists should expect steady-state market management over the next 5–7 years, followed by portfolio restructuring and potential layoffs as cliffs approach.
Breaking In
Entry-level professionals should prioritize Medical Affairs or Commercial roles at J&J, Bayer, or AstraZeneca to build oncology credibility in a stable, well-funded portfolio before seeking higher-risk innovation roles elsewhere.
For Experienced Professionals
Experienced oncology professionals should consider this market for board-level or VP-level roles within established companies, or pivot to emerging mechanisms (ADCs, immunotherapy combos) at biotech to future-proof careers against 2040+ patent cliffs.
In-Demand Skills
Best For
Hiring Landscape
8,207 total jobs across the prostate cancer specialist ecosystem, with Commercial (1,915 roles) and Engineering (547 roles) driving majority of openings. Johnson & Johnson, AstraZeneca, and AbbVie lead hiring with 1,798, 1,373, and 1,495 jobs respectively, reflecting their dominance in the market. Medical Affairs ($302K avg) and Commercial ($225K avg) offer the highest-value career tracks.
By Department
Stable hiring across established players, but growth limited; opportunities concentrate in Commercial and Medical Affairs for those seeking high-impact roles in a mature, well-resourced market.
On Market (10)
Approved therapies currently available
Competitive Landscape
180 companies ranked by most advanced pipeline stage
+150 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (50)
Total enrollment: 16,673 patients across 50 trials
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
GP Extended Action Triptorelin
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
CMAB vs IMAB in Metastatic Prostate Cancer
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Ga-68-PSMA-11 in Men With Prostate Cancer
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
Phase III Radium 223 mCRPC-PEACE III
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Related Jobs in Oncology
Senior Manager, IIS Prostate Cancer Strategy & Forecasting
Global Clinical Program Lead, Cell Therapy, Late Development Oncology
Senior Oncology Account Specialist Prostate Cancer Brooklyn, NY
Medical Lead - Prostate
Prostate Field Medical Director (non-MD)
Customer Service Representative
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.